atai Life Sciences to Participate in Upcoming June Healthcare Conferences

Articles | June 17, 2022

NEW YORK and BERLIN, June 16, 2022 (GLOBE NEWSWIRE) — atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the following upcoming healthcare conferences in June: BIO International Conference Format: Company Presentation – In Person… Read More

atai Life Sciences Reports First Quarter 2022 Financial Results and Business Update

News | May 16, 2022

– Strong execution across atai’s three strategic pillars: rapid acting pharmacological intervention, ongoing digital support and biomarker-driven precision mental health – Key milestones include first subject dosed in Phase 1 KUR-101, launch of drug discovery engine Invyxis, initiation of Psyber usability study in patients and COMPASS’ end of… Read More

atai Life Sciences to Announce First-Quarter 2022 Financial Results

Articles | May 4, 2022

NEW YORK, May 04, 2022 (GLOBE NEWSWIRE) — atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will announce its first-quarter 2022 financial results by posting them on the IR portion of its website. Please visit the atai… Read More